Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: HEPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hepion Pharmaceuticals, Inc. (HEPA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, registration statements and other documents filed with the U.S. Securities and Exchange Commission. Hepion describes itself as a clinical stage biopharmaceutical company that had been developing rencofilstat for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC) and other chronic liver diseases, and that is transitioning toward the development and commercialization of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and HCC.
Through its SEC filings, Hepion reports material events and strategic changes such as executive departures, board decisions and restructuring plans. For example, a current report on Form 8-K details the resignation of a chief financial officer and director. Other filings referenced in company news include registration statements on Form S-1 for public offerings of common stock and warrants, and a registration statement on Form F-4 related to a proposed merger with Pharma Two B Ltd. that was later terminated by mutual agreement.
Filings also document capital structure and listing developments, including the mechanics and rationale of a reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as disclosures surrounding a subsequent delisting notification from Nasdaq. Investors can use these documents to understand how Hepion has managed its equity, responded to listing standards, and transitioned its common stock to trading on the OTCQB Venture Market.
For those analyzing Hepion’s pipeline and asset monetization, SEC filings and incorporated disclosures describe the wind-down and closure of the ASCEND-NASH Phase 2b trial and the sale of rencofilstat-related patents, knowhow, clinical trial data and drug product, along with the grant of a contingent value right to stockholders. Stock Titan’s platform surfaces these filings with AI-powered summaries that highlight key terms, risk factors and transaction details, helping readers navigate complex documents such as registration statements and current reports without having to parse every page manually.
In addition, users can review historical filings related to Hepion’s strategic restructuring plan, its exploration of strategic and financing alternatives, and its shift toward licensed diagnostic tests. Real-time updates from EDGAR combined with AI-generated insights make this page a focused resource for understanding how Hepion’s regulatory disclosures reflect its move from liver drug development to precision diagnostics and its evolving public company status.
Hepion Pharmaceuticals is calling an annual shareholder meeting on June 17, 2026 to elect five directors, ratify its auditor and significantly expand its equity incentive plan. Shareholders are asked to increase the 2023 Omnibus Equity Incentive Plan reserve to 8,000,000 shares, up from 200,000, an increase of 7,800,000 shares. The company notes this would equal about 21.5% of basic shares outstanding and 19.7% on a fully diluted basis as of April 28, 2026. The proxy outlines governance practices, board and committee structure, director biographies, executive pay for 2024–2025, and a proposal to ratify Grassi & Co., CPAs, P.C. as independent auditor for 2026.
Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons, effective immediately on March 16, 2026. The Board moved quickly to reconfigure leadership, naming Gary Stetz as interim CEO and a director the same day.
The Board also appointed Vincent LoPriore as Executive Chairman and added Sireesh Appajosyula and Chase LoPriore as directors. The company states there are no special arrangements behind these appointments and no family relationships between the new leaders and existing directors or executive officers.
Hepion Pharmaceuticals’ annual report outlines a major strategic shift and significant financial risk. The company has exited its prior focus on liver drug rencofilstat, winding down the ASCEND-NASH trial in 2024 and selling all rencofilstat-related assets to Panetta Partners in May 2025 for a nominal amount, with only contingent value rights retained for shareholders.
Hepion is repositioning as a medical diagnostics company, in-licensing CE‑marked tests for celiac disease, respiratory multiplex, H. pylori and hepatocellular carcinoma from New Day Diagnostics in May 2025, and liver disease diagnostic intellectual property from Cirna Diagnostics in February 2026. The New Day arrangement resulted in total consideration of $815,045, all expensed after impairment.
The company has an accumulated deficit of $246.1 million as of December 31, 2025, and discloses substantial doubt about its ability to continue as a going concern, expecting to exhaust available cash during the third quarter of 2026 without additional capital. It raised approximately $8.2 million in 2025 and $4.3 million in 2024 but now has only two employees and no internal manufacturing or commercial infrastructure, relying on third parties for development and future production.